Treatment News : Stribild Receives ‘Alternative’ U.S. Guidelines Ranking

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » September 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


September 18, 2012

Stribild Receives ‘Alternative’ U.S. Guidelines Ranking

Panelists responsible for the U.S. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents have listed Stribild, formerly the Quad, as an “alternative” treatment option for people living with HIV starting therapy for the first time, according to a September 18 summary by the U.S. Department of Health and Human Services (HHS). “Preferred” options remain unchanged: either Atripla, or Norvir-boosted Reyataz, Norvir-boosted Prezista or Isentress combined with Truvada.

Though the panelists underscore that Stribild, approved August 28, is an effective integrase inhibitor-based regimen for first-time treatment takers, they note several limitations that likely prevented the one-pill, once-daily regimen from being listed as a preferred option. These include “a significant potential for drug-drug interactions, the available of only 48 weeks of safety data, usage limited to individuals with [normal kidney function], a possible increased risk of [kidney damage], limited data in patients with advanced HIV disease and in women, and the need for the drug to be taken with food.”

To read the HHS summary, click here

Search: stribild, elvitegravir, cobicistat, tenofovir, emtricitabine, preferred, alternative, dhhs, guidelines, gilead

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.